Association of MyProstateScore (MPS) with prostate cancer grade in the radical prostatectomy specimen.
暂无分享,去创建一个
John T. Wei | A. Chinnaiyan | S. Tomlins | R. Mehra | T. Morgan | J. Tosoian | J. Siddiqui | Y. Niknafs | G. Palapattu | L. Kunju | C. Ellimoottil | S. Salami | Nicholas W. Eyrich | N. Eyrich
[1] Ruth Etzioni,et al. Economic Evaluation of Urine-Based or Magnetic Resonance Imaging Reflex Tests in Men With Intermediate Prostate-Specific Antigen Levels in the United States. , 2021, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[2] John T. Wei,et al. Use of the MyProstateScore (MPS) Test to Rule Out Clinically-Significant Cancer: Validation of a Straightforward Clinical Testing Approach. , 2020, Journal of Urology.
[3] J. Brooks,et al. 17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] V. Laudone,et al. Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance. , 2019, European urology.
[5] S. Serni,et al. Adverse pathology after radical prostatectomy: the prognostic role of cumulative cancer length >6-mm threshold in prostate cancer–positive biopsies , 2019, Prostate International.
[6] T. H. van der Kwast,et al. A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. , 2019, European urology.
[7] D. Lu,et al. Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging. , 2019, European urology.
[8] John T. Wei,et al. Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator. , 2019, European urology focus.
[9] Predictors of adverse pathologic features after radical prostatectomy in low-risk prostate cancer , 2018, BMC Cancer.
[10] H. Bang,et al. Prostate-Specific Antigen–Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force , 2018, JAMA.
[11] Jonathan I. Epstein,et al. Longitudinal Assessment of Urinary PCA3 for Predicting Prostate Cancer Grade Reclassification in Favorable Risk Men during Active Surveillance , 2017, Prostate Cancer and Prostatic Diseases.
[12] D. Sjoberg,et al. The 4Kscore Predicts the Grade and Stage of Prostate Cancer in the Radical Prostatectomy Specimen: Results from a Multi-institutional Prospective Trial. , 2017, European urology focus.
[13] John T. Wei,et al. Association Between Combined TMPRSS2: ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer , 2017, JAMA oncology.
[14] Geert Trooskens,et al. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score. , 2016, European urology.
[15] Javed Siddiqui,et al. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. , 2016, European urology.
[16] H. Hricak,et al. Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference , 2016, European Radiology.
[17] John T. Wei,et al. Assessment of long‐term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy , 2015, Cancer.
[18] T. Tammela,et al. Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening , 2015, Clinical Cancer Research.
[19] David C. Miller,et al. Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer. , 2015, European urology.
[20] Yair Lotan,et al. Can urinary PCA3 supplement PSA in the early detection of prostate cancer? , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Lori J Sokoll,et al. Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer. , 2014, Urology.
[22] Ruth Etzioni,et al. Overdiagnosis and overtreatment of prostate cancer. , 2014, European urology.
[23] T. D. de Reijke,et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. , 2014, European urology.
[24] Yair Lotan,et al. Systematic review of complications of prostate biopsy. , 2013, European urology.
[25] T. H. van der Kwast,et al. Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam. , 2013, European urology.
[26] John T. Wei,et al. Urinary TMPRSS2:ERG and PCA3 in an Active Surveillance Cohort: Results from a Baseline Analysis in the Canary Prostate Active Surveillance Study , 2013, Clinical Cancer Research.
[27] G. Andriole,et al. Risk-based prostate cancer screening. , 2012, European urology.
[28] M. Gleave,et al. Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence , 2011, BJU international.
[29] L. Salomon,et al. Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. , 2011, European urology.
[30] A. Haese*,et al. Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. , 2011, European urology.
[31] Erik Holmberg,et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. , 2010, The Lancet. Oncology.
[32] J. Witjes,et al. Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results , 2008, The Prostate.
[33] I. Tuerk,et al. Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: the Lahey Clinic Medical Center experience and an international meta-analysis. , 2008, European urology.
[34] A. Zlotta,et al. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Glea- son Grading of Prostatic Carcinoma , 2006 .
[35] L. Kiemeney,et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. , 2002, Cancer research.